Sample rows from Lifestyle Diseases. Field types are labelled in each column heading.
#	TextID	TextDisease Name	TextCategory	TextPrevalence	TextInheritance Pattern	TextAffected Gene(s)	LocationChromosome Location	TextKey Symptoms	TextTypical Age of Onset	TextDiagnosis Methods	TextAvailable Treatments	TextOrphan Drug Designation	TextICD-10 Code	NumberOMIM Number	TextAffected System	TextDisease Severity	TextLife Expectancy Impact
01	1	Essential (Primary) Hypertension	Hypertension	~1.4 billion adults aged 30-79 globally (WHO 2024); ~47% US adults (CDC/AHA 2025)	Acquired (excess sodium intake, obesity, physical inactivity, alcohol, low potassium diet, chronic stress, tobacco)	Host: polygenic (AGT, ACE, NOS3, CYP11B2 variants)	1q42-q43, 17q23, 7q36, 8q24	Usually asymptomatic; headache, dizziness, blurred vision, epistaxis when severe; end-organ damage signs	Adults 30-50 years	Office BP >=130/80 confirmed by ambulatory/home BP monitoring per 2017 ACC/AHA; basic labs, ECG, urinalysis, eGFR, lipid panel	Lifestyle (DASH diet, Na <1500 mg/d, exercise, weight loss); thiazide-type (chlorthalidone, hydrochlorothiazide), ACEi (lisinopril/Zestril), ARB (losartan/Cozaar), CCB (amlodipine/Norvasc); target <130/80	No	I10	N/A	Cardiovascular	Variable	Variable
02	2	Hypertensive Heart Disease	Hypertensive Heart Disease	~1.1 million US hospitalizations/yr; leading HTN complication (AHA 2025 Stats)	Acquired (long-standing uncontrolled hypertension, obesity, sedentary lifestyle, high sodium intake)	Host: polygenic (same as essential HTN; AGT, ACE variants)	1q42-q43, 17q23	Dyspnea on exertion, fatigue, chest discomfort, palpitations, orthopnea, LVH on ECG, S4 gallop	Adults 50-70 years	ECG (LVH by Sokolow-Lyon/Cornell), echocardiography (LV mass index, diastolic dysfunction), cardiac MRI, NT-proBNP	Aggressive BP control; ACEi/ARB (lisinopril, losartan) or ARNI (sacubitril/valsartan/Entresto), beta-blocker (metoprolol succinate/Toprol-XL, carvedilol/Coreg), MRA (spironolactone/Aldactone); treat comorbid HF per 2022 AHA/ACC/HFSA HF guideline	No	I11.9	N/A	Cardiovascular	Moderate	Reduced
03	3	Hypertensive Urgency/Emergency	Hypertensive Crisis	~1-2% of HTN patients experience crisis lifetime; ~500,000 US ED visits/yr	Acquired (medication nonadherence, illicit drug use cocaine/methamphetamine, uncontrolled chronic HTN, high sodium intake)	Host: same polygenic variants as essential HTN	1q42-q43, 17q23	Urgency: severe headache, anxiety, epistaxis without organ damage; Emergency: chest pain, dyspnea, neurologic deficits, visual changes, papilledema, AKI	Adults 40-70 years	BP >=180/120; urgency vs emergency distinguished by end-organ damage (ECG, troponin, chest X-ray, BUN/Cr, urinalysis, fundoscopy, head CT)	Urgency: oral agents, gradual reduction over 24-48h (captopril, labetalol, clonidine); Emergency: IV agents (nicardipine/Cardene, labetalol/Normodyne, clevidipine/Cleviprex, nitroprusside); reduce MAP by 10-20% in 1st hour	No	I16.1	N/A	Cardiovascular	Severe	Variable
04	4	Coronary Artery Disease (Atherosclerotic)	Ischemic Heart Disease	~20.5 million US adults (~7.2% ages 20+); 371,506 US deaths in 2022 (CDC/AHA 2025)	Acquired (smoking, dyslipidemia, diabetes, hypertension, obesity, physical inactivity, poor diet, stress)	Host: polygenic (9p21.3 locus, LDLR, APOE, PCSK9 variants)	9p21.3, 19p13.2, 19q13.32, 1p32.3	Often asymptomatic until event; exertional chest pain/pressure, dyspnea, fatigue, angina equivalents	Men >45, women >55 years	ECG, coronary CT angiography (CCTA, preferred initial per 2023 CCD guideline), stress testing, coronary angiography, coronary artery calcium (CAC) score	Lifestyle + high-intensity statin (atorvastatin/Lipitor, rosuvastatin/Crestor), aspirin, ACEi/ARB, beta-blocker; ezetimibe (Zetia), PCSK9i (evolocumab/Repatha, alirocumab/Praluent); revascularization (PCI/CABG) when indicated	No	I25.10	N/A	Cardiovascular	Variable	Reduced
05	5	Stable Angina Pectoris	Chronic Coronary Disease	~9 million US adults with angina; most common symptomatic CAD manifestation (AHA 2025)	Acquired (atherosclerosis risk factors: smoking, dyslipidemia, HTN, DM, obesity, inactivity)	Host: polygenic CAD loci (9p21.3, LPA)	9p21.3, 6q26-q27	Predictable exertional retrosternal chest pressure/tightness, relieved by rest or nitroglycerin (<5-10 min), radiation to jaw/arm	Men >50, women >60 years	History (typical/atypical), ECG, stress testing (exercise, stress echo, SPECT, stress CMR), CCTA, invasive angiography with FFR per 2023 AHA/ACC CCD guideline	Lifestyle, high-intensity statin, aspirin, ACEi; antianginal first-line: beta-blocker (metoprolol/Toprol-XL) OR CCB (amlodipine/Norvasc) OR long-acting nitrate (isosorbide mononitrate/Imdur); ranolazine (Ranexa) 2nd-line; SL nitroglycerin PRN	No	I20.9	N/A	Cardiovascular	Moderate	Reduced

Lifestyle Diseases

About this dataset

Data preview

Explore the sample

There’s more to discover.